JP2025517672A - プロドラッグおよびその使用 - Google Patents

プロドラッグおよびその使用 Download PDF

Info

Publication number
JP2025517672A
JP2025517672A JP2024566410A JP2024566410A JP2025517672A JP 2025517672 A JP2025517672 A JP 2025517672A JP 2024566410 A JP2024566410 A JP 2024566410A JP 2024566410 A JP2024566410 A JP 2024566410A JP 2025517672 A JP2025517672 A JP 2025517672A
Authority
JP
Japan
Prior art keywords
formula
compound
glp
ethoxy
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2024566410A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025517672A5 (cg-RX-API-DMAC7.html
Inventor
バベシュ・プレムジー
イェスパー・エフ・ラウ
セシリー・ミア・ヨルゲンセン
レナート・リッケ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of JP2025517672A publication Critical patent/JP2025517672A/ja
Publication of JP2025517672A5 publication Critical patent/JP2025517672A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2024566410A 2022-05-10 2023-05-09 プロドラッグおよびその使用 Withdrawn JP2025517672A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22172545 2022-05-10
EP22172545.0 2022-05-10
PCT/EP2023/062208 WO2023217744A1 (en) 2022-05-10 2023-05-09 Prodrugs of glp-1 polypeptide and uses thereof

Publications (2)

Publication Number Publication Date
JP2025517672A true JP2025517672A (ja) 2025-06-10
JP2025517672A5 JP2025517672A5 (cg-RX-API-DMAC7.html) 2026-05-01

Family

ID=81940650

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024566410A Withdrawn JP2025517672A (ja) 2022-05-10 2023-05-09 プロドラッグおよびその使用

Country Status (7)

Country Link
US (1) US20250304645A1 (cg-RX-API-DMAC7.html)
EP (1) EP4522220A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025517672A (cg-RX-API-DMAC7.html)
CN (1) CN119173275A (cg-RX-API-DMAC7.html)
AR (1) AR129270A1 (cg-RX-API-DMAC7.html)
TW (1) TW202346324A (cg-RX-API-DMAC7.html)
WO (1) WO2023217744A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120659805A (zh) * 2023-10-31 2025-09-16 深圳信立泰药业股份有限公司 Glp-1化合物及其制备方法与应用
WO2026052063A1 (en) * 2024-09-06 2026-03-12 Suzhou Spring-Sea Bio-Pharmaceuticals Co. Ltd. Glp-1 polypeptide prodrugs and uses thereof
WO2026139053A1 (zh) * 2024-12-27 2026-07-02 深圳信立泰药业股份有限公司 一种包含glp-1化合物的药物组合物及其制备方法与应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7238671B2 (en) * 2001-10-18 2007-07-03 Bristol-Myers Squibb Company Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
JP2012512898A (ja) 2008-12-19 2012-06-07 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション ジペプチド結合薬用剤
EP2376097A4 (en) 2008-12-19 2012-10-03 Univ Indiana Res & Tech Corp PEPTIDE PRODRUGS OF AMIDE-BASED GLUCAGON SUPERFAMILY
US20110306551A1 (en) 2009-02-19 2011-12-15 Novo Nordisk A/S Modification of Factor VIII
US20120329711A1 (en) 2009-12-16 2012-12-27 Nordisk A/S Glp-1 receptor agonist compounds with a modified n-terminus
US9062094B2 (en) 2010-01-22 2015-06-23 Ascendis Pharma As Dipeptide-based prodrug linkers for aliphatic amine-containing drugs
US8778872B2 (en) 2010-06-24 2014-07-15 Indiana University Research And Technology Corporation Amide based glucagon superfamily peptide prodrugs
JP6231386B2 (ja) 2010-11-09 2017-11-15 ノヴォ ノルディスク アー/エス リンカーを有する二重アシル化されたglp−1誘導体
ES2810153T3 (es) 2012-03-01 2021-03-08 Novo Nordisk As Profármacos de GLP-1
US20160058881A1 (en) 2013-03-15 2016-03-03 Indiana University Research And Technology Corporation Prodrugs with prolonged action
EP3197912B1 (en) 2014-09-24 2023-01-04 Indiana University Research & Technology Corporation Lipidated amide-based insulin prodrugs
AR114353A1 (es) 2018-02-02 2020-08-26 Novo Nordisk As Composiciones sólidas que comprenden un agonista del glp-1 y una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico
TWI829687B (zh) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物

Also Published As

Publication number Publication date
EP4522220A1 (en) 2025-03-19
CN119173275A (zh) 2024-12-20
US20250304645A1 (en) 2025-10-02
WO2023217744A1 (en) 2023-11-16
AR129270A1 (es) 2024-08-07
TW202346324A (zh) 2023-12-01

Similar Documents

Publication Publication Date Title
JP7484018B2 (ja) Glp-1プロドラッグおよびその使用
US10604555B2 (en) GIP derivatives and uses thereof
US11866477B2 (en) GLP-1 analogues
JP6352806B2 (ja) 新規のグルカゴン類似体
AU2006224536B2 (en) Acylated GLP-1 compounds
US20250304645A1 (en) Prodrugs of GLP-1 Polypeptide and Uses Thereof
CN116490212A (zh) Glp-1前药及其用途
JP7434616B2 (ja) プロドラッグおよびその使用
JP2007537141A (ja) 新規なglp−1化合物
CN102076353A (zh) 胰岛淀粉样多肽和鲑鱼降钙素的衍生杂合肽
CA3195872A1 (en) Glp-1 prodrugs and uses hereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260422

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260422

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20260709